As treatment response to FLT3 inhibitors may be short-lived, with leukemia relapse as the major cause of treatment failure, compounds targeting STAT5 may enhance and prolong effects of FLT3 inhibitors in this subset of patients with FLT3-mutated AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.